NCT05044039View on ClinicalTrials.gov

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2030

Conditions
Non-hodgkin LymphomaAcute Lymphocytic Leukemia
Interventions
DRUG

Duvelisib

Patients should take duvelisib at approximately the same time every day, with or without food.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

SecuraBio

INDUSTRY

collaborator

The Foundation for Barnes-Jewish Hospital

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Washington University School of Medicine

OTHER